AMY-101 acetate (Cp40 acetate) 是补体 C3 的肽类抑制剂 (K_D = 0.5 nM)，可抑制非人类灵长类动物自然发生的牙周炎。AMY-101 acetate (Cp40 acetate) 在 COVID-19 重症肺炎合并全身超炎症模型中具有良好的抗炎活性。

AMY-101 acetate (Cp40 acetate), a peptidic inhibitor of the central complement component C3 (K D = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 acetate (Cp40 acetate) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation.

Solid

KD: 0.5 nM (C3).

AMY-101 can improve the periodontal condition of NHPs with natural chronic periodontitis.
AMY-101 can induce a long-lasting anti-inflammatory effect.
AMY-101 (4 mg/kg bodyweight, subcutaneous injection. once per 24 hr for a total of 28 days) causes a significant and long-lasting reduction in PPD, an index that measures tissue destruction.
AMY-101 (Cp40, 1 mg/kg, sc, injection every 12 h, daily, 7 or 14 days) attenuates fibrosis and infiltration of inflammatory cells in UUO-induced renal fibrosis. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture and lightPowder -80°C 2 years；-20°C 1 year

YICV-{Trp(Me)}-QDW-{Sar}-AHRC-{N(Me)Ile}-NH2 (Disulfide bridge:Cys3-Cys13)

[1]. Kajikawa T, et al. Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Mol Ther Methods Clin Dev. 2017 Aug 18;6:207-215.
[2]. Mastaglio S, et al. The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol. 2020 Apr 29:108450.

In Vitro: DMSO : 100 mg/mL (54.08 mM; Need ultrasonic)H₂O : 50 mg/mL (27.04 mM; Need ultrasonic)配制储备液